The Vitals | The Living Brain Project

Why It Matters

By unlocking live human brain tissue for research, the Living Brain Project could accelerate the development of precision therapies for neuropsychiatric diseases, turning genetic and circuit insights into tangible clinical benefits.

Key Takeaways

• Neuroscience and psychiatry converge; distinction is historically outdated.
• Brain disorders are polygenic, not caused by single genes.
• Living brain tissue sampling via DBS offers unprecedented research access.
• Data explosion reshapes disease definitions toward overlapping continuums.
• Translational gap persists; genetics insights haven’t yet changed treatments.

Summary

The Vitals episode spotlights Mount Sinai’s Living Brain Project, a collaborative roundtable that brings together a psychiatrist and a neurosurgeon to examine how modern neuroscience is blurring the lines between neurology and psychiatry. Host Leslie Schlachter frames the discussion around the project’s ambition to study live human brain tissue, a paradigm shift from traditional post‑mortem analyses.

Panelists emphasize two transformative insights from the past two decades: the genetic architecture of brain disorders is highly polygenic, and advances in imaging and sequencing now generate massive, multidimensional data sets. These developments reveal that conditions such as Parkinson’s disease, depression, and schizophrenia share overlapping molecular and circuit‑level features, challenging the century‑old view of discrete disease categories.

Dr. Charney argues that “there is no distinction between neurology and psychiatry” at the scientific level, while Dr. Kopell describes how deep‑brain stimulation surgeries provide a safe conduit to harvest millimeter‑scale brain biopsies. To date, the Living Brain Project has amassed close to a thousand live‑tissue samples, far exceeding the previously reported 300, creating an unprecedented repository for mechanistic studies.

The implications are profound: a richer, continuum‑based understanding of brain disorders could drive next‑generation, circuit‑targeted therapies, yet the translational gap remains wide. Bridging this divide will require integrating genetic risk scores, high‑resolution imaging, and live tissue insights to move from discovery to clinical impact, ultimately reshaping patient care.

Original Description

What can living brain tissue reveal that decades of neuroscience could not?

In this episode of The Vitals, host Leslie Schlachter sits down with Alex Charney and Brian Kopell to discuss the Living Brain Project, one of the most ambitious neuroscience efforts underway at the Mount Sinai Health System. By safely collecting tiny biopsies during deep brain simulation surgery, researchers are studying the living human brain in ways previously thought impossible.

The conversation explores why living brain tissue differs dramatically from postmortem samples, how this research is already helping validate next-generation gene therapies, and why collaboration between neurosurgeons and molecular scientists may unlock entirely new treatments for neurological and psychiatric disease.

--------------------------------------------

00:01:27 — Why psychiatry and neurology overlap

00:05:05 — A major game-changer

00:10:34 — Introduction: the Living Brain Project

00:16:54 — Surgical approach and rationale

00:23:03 — Early key result

00:24:37 — Major discovery: Brain differences

00:32:06 — The “moonshot"

00:47:00 — Misinformation highlighted